Oncology Archives - Page 18 of 22

Lost Annual Productivity Costs Due to Uterine Cancer Deaths in the United States in 2014

Authors: S Corman, C Nwankwo Published: Journal of Women's Health, 2019 View publication BACKGROUND An estimated 11,350 uterine cancer deaths are projected to occur in the United States in 2018. We constructed...

Overall survival, costs, and healthcare resource use by line of therapy in medicare patients with newly diagnosed metastatic urothelial carcinoma

Authors: A Aly, C Johnson, S Yang, M F Botteman, S Rao, A Hussain. Published: Journal of Medical Economics, 2019 View publication Aims Medicare patients with metastatic or surgically unresectable urothelial carcinoma...

Health state utilities for acute myeloid leukaemia: a time trade-off study

Authors: N Joshi, M Hensen, S Patel, W Xu, K Lasch, E Stolk Published: Pharmacoeconomics, 2019 View publication Objectives Acute myeloid leukaemia (AML) is an aggressive haematological cancer associated with significant humanistic...

Medical Resource Utilization and Costs from Subsequent Metastasis in Prostate Cancer (PC) Patients Initially Diagnosed with Locoregional Disease

Authors: Li, Shore N.; Mehra, M.; Todd, M.; Saadi. R.; Leblay, G.; Griffiths, R.; Aggarwal, J. Published: ASCO, 2016 View publication Background In prostate cancer (PC), progression from locoregional to metastatic disease...

Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China

Authors: G Shi, S H Park, H Ren, M Xue, X Lu, P Dong, X Gao Published: Journal of Medical Economics, 2018 View publication Purpose Targeted therapies including sunitinib, sorafenib, axitinib, and...

Quality-adjusted survival with nab-paclitaxel versus standard paclitaxel in metastatic breast cancer: a Q-TWiST analysis

Authors: J Cortes, J Perez-Garcia, S Whiting, Y Wan, C Solem, M H Tai, S Margunato-Debay, A Ko, A Fandi, M Botteman Published: Clinical Breast Cancer, 2018 View publication Background In this...

Quality-adjusted outcomes stratified by response in patients with advanced non-small-cell lung cancer receiving first-line nab-paclitaxel/carboplatin or paclitaxel/carboplatin

Authors: V Hirsh, Y Wan, F J Lin, S Marqunato-Debay, T J Ong, M Botteman, C Langer Published: Clinical Lung Cancer, 2018 View publication Background First-line nab-paclitaxel/carboplatin was associated with a significantly...

Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada

Authors: WY Cheung; MK White; MS Bayliss; A Stroupe; A Lovley; BL King-Kallimanis; K Lasch Published: Support Care Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer, 2018 View...

Nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial

Authors: R Young, P Mainwaring, P Clingan, FX Parnis, G Asghari, P Beale, A Aly, M Botteman, A Romano, S Ferrara, S Margunato-Debay, M Harris Published: Asia-Pacific Journal of Clinical Oncology, 2018...

News